Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered AMG 900 in Adult Subjects With Advanced Solid Tumors

NCT00858377 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00858377
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00858377 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered AMG 900 in Adult Subjects With Advanced Solid Tumors
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Completed
Start date
August 10, 2009
Completion date
April 3, 2019
Enrollment
95 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignancy, advanced solid tumors, cancer, solid tumors, tumors